This site is intended for healthcare professionals
Drug news

Laquinimod in Phase II LEGATO-HD trial to treat Huntington's disease did not met its primary endpoint.- Active Biotech + Teva.

Read time: 1 mins
Last updated:1st Aug 2018
Published:1st Aug 2018
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest